Biotechnology
Medical
Biopharmaceutical

Puma Biotechnology

$16.97
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.29 (-1.72%) Today
+$0.38 (2.29%) After Hours

Why Robinhood?

You can buy or sell PBYI and other stocks, options, ETFs, and crypto commission-free!

About

Puma Biotechnology Inc Common Stock, also called Puma Biotechnology, is a development stage biopharmaceutical company. It acquires and develops innovative products for the treatment of various forms of cancer. Read More The company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seek to further develop those drug candidates for commercial use. Puma Biotechnology was founded by Alan H. Auerbach on September 15, 2010 and is headquartered in Los Angeles, CA.

Employees
272
Headquarters
Los Angeles, California
Founded
2010
Market Cap
639.93M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
1.09M
High Today
$17.13
Low Today
$16.58
Open Price
$16.68
Volume
422.18K
52 Week High
$65.45
52 Week Low
$15.96

Collections

Biotechnology
Medical
Biopharmaceutical
Pharmaceutical
Health
Cancer Prevention
Technology

News

Seeking AlphaMay 10

Puma Biotechnology, Inc. CEO Alan Auerbach on Q1 2019 Results - Earnings Call Transcript

Puma Biotechnology, Inc. (NASDAQ:PBYI) Q1 2019 Results Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants Mariann Ohanesian - Investor Relations Alan Auerbach - President & Chief Executive Officer Steve Lo - Chief Commercial Officer Maximo Nougues - Chief Financial Officer Conference Call Participants Yigal Nochomovitz - Citigroup Varun Kumar - Cantor Fitzgerald Corinne Jenkins - Goldman Sachs Chris Shibutani - Cowen Kennen MacKay - RBC Capital Markets Michael Schmidt - Guggenh...

833
Yahoo FinanceMay 10

Puma Biotech Q1 Earnings Top, Nerlynx Disappoints

Puma Biotechnology, Inc. PBYI incurred a loss of 26 cents per share for the first quarter of 2019, narrower than the Zacks Consensus Estimate of a loss of 69 cents as well as the year-ago loss of 65 cents. Total revenues consist of both net product revenues from the sales of Nerlynx (neratinib) and the company’s license revenues. In the first quarter of 2019, total revenues came in at $99.1 million, comprising $45.6 million of product revenues from Nerlynx and $53.5 million of license revenues. Moreover, s...

694
Yahoo FinanceMay 10

Puma Biotech Reports Q1 Loss, Tops Revenue Estimates

204

Earnings

-$2.49
-$1.75
-$1.00
-$0.26
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
-$0.68 per share
Actual
-$0.26 per share

Popular Stocks

All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.